Welcome to our dedicated page for West Pharm Svcs news (Ticker: WST), a resource for investors and traders seeking the latest updates and insights on West Pharm Svcs stock.
West Pharmaceutical Services, Inc. (NYSE: WST) is a provider of injectable solutions and services that support the containment and delivery of medicines for pharmaceutical, biotechnology and generic drug companies. News related to WST often centers on its role in injectable drug administration, its proprietary product platforms and its contract manufacturing activities.
Company announcements frequently include quarterly and annual financial results, updates to revenue and earnings guidance, and details on performance in its Proprietary Products and Contract-Manufactured Products segments. Releases have highlighted trends in High-Value Product Components and High-Value Product Delivery Devices, as well as demand for self-injection devices for therapeutic areas such as obesity and diabetes.
West’s news flow also covers product and technology developments. Recent examples include the launch of the West Synchrony™ Prefillable Syringe System, described as a system-level solution for biologics and vaccines, and updates on the SmartDose® on-body delivery platform. The company has announced a definitive agreement to sell manufacturing and supply rights for the SmartDose® 3.5mL On-Body Delivery System and associated facilities to AbbVie, along with related information on continued supply and ongoing project commitments.
Investors following WST news will also see disclosures about capital allocation, such as dividends and share repurchases, as well as governance and leadership changes reported via press releases and Form 8-K filings. Conference participation and investor presentations are regularly announced, providing additional context on the company’s strategy and financial outlook. This news page aggregates such updates so readers can review West’s latest reported developments, financial communications and product-related announcements in one place.
West Pharmaceutical Services (NYSE: WST) announced its participation at Pharmapack Europe 2023, showcasing innovations in injectable drug packaging. The company introduced three new products: West Ready Pack™ with Corning Valor® RTU Vials, Daikyo Crystal Zenith® 2.25mL Insert Needle Syringe System, and FluroTec® 5-10mL Cartridge Plunger. These innovations aim to address the demands of complex drug delivery and enhance patient safety. Additionally, West's presentations include discussions on market trends and innovations in drug delivery systems, highlighting the company's ongoing commitment to improving patient adherence and pharmaceutical solutions.
West Pharmaceutical Services, Inc. (NYSE: WST), a leader in injectable drug solutions, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 12, 2023, at 9:00 am PST. A live audio webcast will be available on the company's website, with a replay accessible for 90 days. With nearly 10,000 employees across 50 sites, West generated $2.83 billion in net sales in 2021, providing crucial containment and delivery services for medicines worldwide. For more insights, visit www.westpharma.com.
West Pharmaceutical Services, Inc. (NYSE: WST) has declared a first-quarter 2023 dividend of $0.19 per share, payable on February 1, 2023, to shareholders of record by January 25, 2023. The company reported $2.83 billion in net sales for its fiscal year 2021, highlighting its position as a leader in injectable drug administration solutions. West will also participate in the CJS Securities 23rd Annual "New Ideas for the New Year" Conference on January 11, 2023, at 3:05 pm ET.
West Pharmaceutical Services, Inc. (NYSE: WST) announced participation in two key investor conferences. The company will present at the Jefferies London Healthcare Conference on November 15, 2022, at 3:50 PM GMT, and at the Stephens Annual Investment Conference in Nashville, TN, on November 17, 2022, at 2:00 PM CT. Live audio webcasts of both presentations will be available on the company's website, with replays accessible for 90 days post-event. West generated $2.83 billion in net sales in fiscal year 2021 and operates about 50 sites globally, employing approximately 10,000 team members.
West Pharmaceutical Services, Inc. (NYSE: WST) will participate in CPhI Worldwide in Frankfurt, Germany, on November 1, 2022. The company aims to address industry challenges in packaging and containment. Chris Ryan, VP at West, emphasized their collaboration with Corning for advanced solutions in lyophilization and closure integrity. Experts will present on elastomer formulations and container closure systems at scheduled speaking sessions. West, headquartered in Exton, Pennsylvania, reported $2.83 billion in net sales in fiscal year 2021.
West Pharmaceutical Services (WST) reported third-quarter 2022 net sales of $686.9 million, down 2.8%, with organic growth at 4.3%. Reported diluted EPS declined by 31.2% to $1.59, while adjusted diluted EPS fell 1.5% to $2.03. The company updated its full-year net sales guidance to $2.830 billion - $2.840 billion, down from $2.950 billion - $2.975 billion. A quarterly dividend of $0.19, a 5.6% increase, will be paid on November 16, 2022. The CEO anticipates 2023 organic growth exceeding 7%, despite declining COVID-related sales.
West Pharmaceutical Services (NYSE: WST) announced its participation in the 2022 PDA Universe of Pre-Filled Syringes and Injection Devices Conference on October 18, 2022. The company aims to showcase its expertise in drug delivery innovation, focusing on challenges in packaging and containment. Cindy Reiss-Clark, Chief Commercial Officer, highlighted the importance of evolving healthcare needs and technological advancements. West will present several technical sessions, including topics on customized injection profiles and sustainable device selection. In fiscal year 2021, West generated $2.83 billion in net sales.
West Pharmaceutical Services (NYSE: WST) will announce its third-quarter 2022 financial results before market opens on October 27, 2022. Following the announcement, a conference call will be held at 9:00 a.m. Eastern Time to discuss the results and future business expectations. The live audio webcast will be available on the company's Investor Relations website. Interested participants can register in advance to ask questions during the call. A replay will be accessible for 30 days post-event.
West Pharmaceutical Services (NYSE: WST) has been shortlisted for the 2022 Global Generics and Biosimilar Awards, with the winner to be announced on November 2, 2022, at CPhI Worldwide in Frankfurt, Germany. This recognition underscores West's commitment to enhancing patient care through innovative drug delivery solutions. In fiscal year 2021, West achieved net sales of $2.83 billion, reflecting its position as a key player in the injectable solutions market.
West Pharmaceutical Services, traded on NYSE: WST, will participate in the Bank of America Global Healthcare Conference on September 15, 2022, at 1:20 pm BST in London, UK. A live audio webcast will be accessible via the company's website, with a replay available for 90 days post-event. West, a leader in injectable drug solutions, generated $2.83 billion in net sales in 2021 and employs approximately 10,000 team members globally.